vTv Therapeutics (NASDAQ:VTVT) Stock Rating Reaffirmed as “Buy” by BTIG Research

vTv Therapeutics (NASDAQ:VTVT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a research report issued on Wednesday, Benzinga reports. They presently have a $57.00 price objective on the biotechnology company’s stock. BTIG Research’s price objective would suggest a potential upside of 98.99% from the company’s previous close.

A number of other research analysts have also weighed in on the company. Wall Street Zen raised vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Lifesci Capital upgraded vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. Rodman & Renshaw began coverage on vTv Therapeutics in a research report on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price for the company. Weiss Ratings downgraded vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, HC Wainwright lowered their target price on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $55.83.

Get vTv Therapeutics alerts:

Check Out Our Latest Report on vTv Therapeutics

vTv Therapeutics Trading Up 1.5%

Shares of NASDAQ:VTVT traded up $0.42 during trading on Wednesday, hitting $28.65. 2,044 shares of the company were exchanged, compared to its average volume of 53,433. The stock has a market cap of $112.86 million, a price-to-earnings ratio of -27.02 and a beta of 0.21. vTv Therapeutics has a fifty-two week low of $19.50 and a fifty-two week high of $44.00. The firm has a fifty day moving average price of $31.90 and a two-hundred day moving average price of $33.55.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.08). As a group, research analysts predict that vTv Therapeutics will post -2.35 EPS for the current year.

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.

Read More

• Five stocks we like better than vTv Therapeutics
• Birkenstock’s Strong Growth Creates a Buying Opportunity
• High Voltage Returns: Navitas Rewires AI Data Centers
• Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
• Albertsons Is Betting on a Turnaround—But Will It Pay Off?

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.